Pelthos Therapeutics Inc. (PTHS)

Valuation on Pelthos Therapeutics Inc. (PTHS) is stretched relative to sovereign debt yields, but short interest is too crowded to bet on immediate downside.

Secondary debt liquidity for PTHS proxies remains highly resilient despite headline noise. Watching gross margin expansion.

On our desk, the valuation narrative for PTHS is a classic tug-of-war between commercial momentum and balance sheet stress. Zelsuvmi is clearly moving through the channel—posting $15.4 million in Q2 product revenue with over 11,900 units dispensed—which justifies Oppenheimer holding an Outperform rating with a $64 price target. However, looking closely at the 10-Q filing details, the cash position has dwindled to $24.2 million against $138.9 million in total liabilities, including $43.3 million in related-party notes and a $26.6 million venture loan. If you are trading the momentum, you have to respect the 45% quarter-over-quarter revenue growth, but the widening net loss of $23.4 million in Q2 means dilution or additional financing risk is lurking right around the corner.

In our clinic, Zelsuvmi has become a prominent discussion point for managing molluscum contagiosum, particularly given its pediatric indication starting at one year of age. The clinical utility is evident in the adoption metrics: 4,571 unique prescribers dispensed units in Q2 alone, pushing cumulative patient adoption past 25,000 since the July 2025 launch. From a clinical adoption standpoint, physicians are clearly receptive to a topical gel alternative for an infection that historically lacked targeted therapies. The key question for us moving forward is whether patient persistence matches initial prescription generation, which will dictate long-term commercial stickiness.